Open AccessPulmonary intravascular large B-cell lymphoma successfully treated with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisolone immunochemotherapy: Report of a patient surviving for over 1 year
Author(s) -
Shizuka NishiiIto,
Hiroki Izumi,
Hirokazu Touge,
Kazuhisa Takeda,
Yuzuru Hosoda,
Akira Yamasaki,
Satoshi Kuwamoto,
Eiji Shimizu,
Toru Motokura
Publication year - 2016
Publication title -
molecular and clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.442
H-Index - 7
eISSN - 2049-9469
pISSN - 2049-9450
DOI - 10.3892/mco.2016.1063
Subject(s) - intravascular large b cell lymphoma , medicine , vincristine , rituximab , prednisolone , cyclophosphamide , lymphoma , fever of unknown origin , radiology , lethargy , pathology , chemotherapy
A 73-year-old man with a history of lethargy, fever and dyspnea was admitted to Tottori University Hospital. A computed tomography (CT) scan revealed splenomegaly and diffusely spreading ground-glass opacities (GGOs) in both lungs. A video-assisted thoracoscopic surgery (VATS)-guided lung biopsy revealed intravascular proliferation of large atypical lymphoid cells in the arteries, veins and alveolar walls. The patient was diagnosed with intravascular large B-cell lymphoma (IVLBCL); he received 6 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) immunochemotherapy and has remained in complete remission for >1 year. Although IVLBCL is a rare disease, it should be considered in the differential diagnosis of pulmonary diffuse lesions that present with GGOs on CT scans.